Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 8 | 2025 | 578 | 1.130 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2025 | 9 | 0.890 |
Why?
|
| Folic Acid | 1 | 2020 | 285 | 0.560 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 159 | 0.520 |
Why?
|
| Mutation | 8 | 2026 | 6146 | 0.480 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2025 | 545 | 0.450 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2025 | 162 | 0.450 |
Why?
|
| Hemoglobinuria, Paroxysmal | 5 | 2024 | 21 | 0.380 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2021 | 31 | 0.340 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 312 | 0.320 |
Why?
|
| Signal Transduction | 1 | 2020 | 4668 | 0.280 |
Why?
|
| Protein Phosphatase 2C | 1 | 2026 | 59 | 0.240 |
Why?
|
| Telomere Shortening | 1 | 2025 | 33 | 0.230 |
Why?
|
| Prognosis | 3 | 2025 | 4933 | 0.210 |
Why?
|
| Telomere | 1 | 2025 | 219 | 0.210 |
Why?
|
| Hematopoiesis | 1 | 2025 | 212 | 0.200 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 153 | 0.200 |
Why?
|
| Disease Susceptibility | 1 | 2025 | 281 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2023 | 163 | 0.190 |
Why?
|
| Germ-Line Mutation | 1 | 2025 | 373 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 133 | 0.180 |
Why?
|
| Leukemia | 1 | 2025 | 374 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 384 | 0.180 |
Why?
|
| Minors | 1 | 2021 | 4 | 0.180 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 69 | 0.170 |
Why?
|
| Refugees | 1 | 2021 | 41 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 220 | 0.170 |
Why?
|
| Disease Management | 1 | 2025 | 563 | 0.170 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 121 | 0.170 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 284 | 0.160 |
Why?
|
| Histones | 2 | 2021 | 543 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 691 | 0.160 |
Why?
|
| Mitochondria | 1 | 2025 | 761 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2021 | 356 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 978 | 0.150 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 70 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 314 | 0.140 |
Why?
|
| Antioxidants | 1 | 2020 | 335 | 0.140 |
Why?
|
| Aging | 1 | 2025 | 1252 | 0.140 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 168 | 0.130 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 1215 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 576 | 0.130 |
Why?
|
| Glutamine | 1 | 2018 | 204 | 0.120 |
Why?
|
| Humans | 19 | 2026 | 130749 | 0.120 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 3698 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2012 | 566 | 0.110 |
Why?
|
| Prevalence | 3 | 2026 | 2683 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 618 | 0.100 |
Why?
|
| Disease Progression | 1 | 2019 | 2202 | 0.090 |
Why?
|
| Hemosiderin | 1 | 2012 | 2 | 0.090 |
Why?
|
| Iron Overload | 1 | 2012 | 18 | 0.090 |
Why?
|
| Animals | 5 | 2025 | 33873 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 35 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2474 | 0.080 |
Why?
|
| Complement C3 | 1 | 2009 | 43 | 0.070 |
Why?
|
| Neoplasms | 1 | 2023 | 2956 | 0.070 |
Why?
|
| Erythrocytes | 1 | 2009 | 191 | 0.070 |
Why?
|
| Male | 9 | 2026 | 64669 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 4695 | 0.060 |
Why?
|
| Middle Aged | 6 | 2025 | 28494 | 0.060 |
Why?
|
| Female | 9 | 2026 | 70618 | 0.060 |
Why?
|
| RNA Splicing Factors | 1 | 2025 | 51 | 0.060 |
Why?
|
| Electron Transport Complex I | 1 | 2025 | 31 | 0.060 |
Why?
|
| Clone Cells | 1 | 2025 | 153 | 0.050 |
Why?
|
| Telomerase | 1 | 2025 | 155 | 0.050 |
Why?
|
| Mice | 4 | 2025 | 18203 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2025 | 129 | 0.050 |
Why?
|
| Bone Marrow Diseases | 1 | 2024 | 45 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2009 | 755 | 0.050 |
Why?
|
| Metformin | 1 | 2025 | 168 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2025 | 351 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2023 | 106 | 0.050 |
Why?
|
| Forensic Sciences | 1 | 2021 | 3 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2026 | 733 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 153 | 0.040 |
Why?
|
| Family | 1 | 2023 | 586 | 0.040 |
Why?
|
| Genotype | 1 | 2026 | 2610 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 274 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2021 | 356 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4653 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 380 | 0.040 |
Why?
|
| Adult | 4 | 2025 | 31266 | 0.040 |
Why?
|
| Software | 1 | 2023 | 736 | 0.030 |
Why?
|
| THP-1 Cells | 1 | 2018 | 21 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 279 | 0.030 |
Why?
|
| DNA | 1 | 2023 | 1413 | 0.030 |
Why?
|
| K562 Cells | 1 | 2018 | 97 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 241 | 0.030 |
Why?
|
| Base Sequence | 1 | 2021 | 2746 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2019 | 738 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 671 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 586 | 0.030 |
Why?
|
| Aged | 2 | 2025 | 20956 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 1380 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 590 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2557 | 0.030 |
Why?
|
| Young Adult | 2 | 2025 | 10021 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2020 | 794 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 2904 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 317 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2146 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3416 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 6783 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2011 | 8 | 0.020 |
Why?
|
| Adolescent | 2 | 2025 | 20832 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1790 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 263 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1838 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5088 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 462 | 0.020 |
Why?
|
| Splenectomy | 1 | 2008 | 62 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2008 | 287 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2025 | 17672 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 839 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 770 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1272 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3869 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 12908 | 0.010 |
Why?
|